We are live on
!
Find out more
Marshall Wace North America Portfolio holdings
AUM
$23.5B
Turnover
51.87%
1-Year Est. Return
46.46%
This Fund
S&P 500
This Quarter
Est. Return
+0.93%
1 Year Est. Return
+46.46%
3 Year Est. Return
+108.51%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$23.5B
AUM Growth
-$574M
(-2.4%)
Cap. Flow
-$385M
Cap. Flow
% of AUM
-1.64%
Top 10 Holdings %
Top 10 Hldgs %
23.48%
Holding
1,876
New
481
Increased
362
Reduced
407
Closed
492
Avg Time Held Equity + Options
0.6
years
Top 10 Avg Time Held Equity + Options
1.3
years
Top 20 Avg Time Held Equity + Options
1.1
years
Avg Time Held Equity only
0.7
years
Top 10 Avg Time Held Equity only
1.3
years
Top 20 Avg Time Held Equity only
1.1
years
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Uber
UBER
|
+$232M |
| 2 |
Cisco
CSCO
|
+$212M |
| 3 |
Pfizer
PFE
|
+$187M |
| 4 |
Lamb Weston
LW
|
+$172M |
| 5 |
Comcast
CMCSA
|
+$156M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Danaher
DHR
|
+$286M |
| 2 |
Meta Platforms (Facebook)
META
|
+$165M |
| 3 |
Elevance Health
ELV
|
+$160M |
| 4 |
Salesforce
CRM
|
+$160M |
| 5 |
TJX Companies
TJX
|
+$147M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 22.34% |
| 2 | Healthcare | 20.96% |
| 3 | Communication Services | 13.02% |
| 4 | Consumer Discretionary | 11.83% |
| 5 | Financials | 9.69% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
926
DELISTED
Taylor Morrison
TMHC
| $982K | ﹤0.01% |
+38,092
| New | +$1.01M |
2021 Q3
0 quarters
|
|
927
DELISTED
Exact Sciences
EXAS
| $979K | ﹤0.01% |
10,251
+8,459
| +472% | +$893K |
2020 Q4
3 quarters
|
|
|
EPWR
928
DELISTED
Empowerment & Inclusion Capital I Corp.
EPWR
| $978K | ﹤0.01% |
100,000
| – | – |
2021 Q1
2 quarters
|
|
|
LGACW
929
CALL
DELISTED
Lazard Growth Acquisition Corp. I Warrants
LGACW
| $973K | ﹤0.01% |
100,000
| – | – |
2021 Q2
1 quarter
|
|
930
Ralph Lauren
RL
$22.9B
| $971K | ﹤0.01% |
8,746
-15,922
| -65% | -$1.84M |
2020 Q4
3 quarters
|
|
|
PDOT.WS
931
CALL
DELISTED
Peridot Acquisition Corp. II Redeemable warrants included as part of the units, each whole warrant exercisable for one Class A ordinary share at an exercise price of $11.50
PDOT.WS
| $971K | ﹤0.01% |
100,000
| – | – |
2021 Q2
1 quarter
|
|
932
Open Text
OTEX
$6.15B
| $966K | ﹤0.01% |
+19,800
| New | +$1.03M |
2021 Q3
0 quarters
|
|
|
KDMN
933
DELISTED
Kadmon Holdings, Inc.
KDMN
| $965K | ﹤0.01% |
+110,852
| New | +$631K |
2021 Q3
0 quarters
|
|
934
National Health Investors
NHI
$3.25B
| $963K | ﹤0.01% |
+18,010
| New | +$1.13M |
2021 Q3
0 quarters
|
|
935
DELISTED
BIOATLA INC
BCAB
| $960K | ﹤0.01% |
652
+29
| +5% | +$56.5K |
2021 Q2
1 quarter
|
|
936
Lloyds Banking Group
LYG
$78.4B
| $959K | ﹤0.01% |
391,206
-1,628,529
| -81% | -$3.99M |
2020 Q4
3 quarters
|
|
937
Beazer Homes USA
BZH
$893M
| $958K | ﹤0.01% |
+55,526
| New | +$994K |
2021 Q3
0 quarters
|
|
938
Levi Strauss
LEVI
$7.78B
| $958K | ﹤0.01% |
39,055
+4,610
| +13% | +$124K |
2021 Q2
1 quarter
|
|
939
Neogen
NEOG
$2.55B
| $958K | ﹤0.01% |
+22,056
| New | +$959K |
2021 Q3
0 quarters
|
|
940
Arbutus Biopharma
ABUS
$842M
| $955K | ﹤0.01% |
+222,739
| New | +$742K |
2021 Q3
0 quarters
|
|
941
Elanco Animal Health
ELAN
$11.8B
| $955K | ﹤0.01% |
29,944
-1,239,373
| -98% | -$41.6M |
2020 Q3
4 quarters
|
|
942
OSI Systems
OSIS
$3.11B
| $954K | ﹤0.01% |
+10,068
| New | +$980K |
2021 Q3
0 quarters
|
|
943
Quest Diagnostics
DGX
$25.8B
| $951K | ﹤0.01% |
6,541
-47,448
| -88% | -$6.94M |
2017 Q1
18 quarters
|
|
944
DocGo
DCGO
$26.5M
| $942K | ﹤0.01% |
94,707
-4,393
| -4% | -$43.6K |
2021 Q1
2 quarters
|
|
|
IVAN.WS
945
CALL
DELISTED
Ivanhoe Capital Acquisition Corp. Warrants, each whole warrant exercisable for one share of Class A
IVAN.WS
| $936K | ﹤0.01% |
94,537
| – | – |
2021 Q1
2 quarters
|
|
946
Immunocore
IMCR
$1.54B
| $932K | ﹤0.01% |
25,144
| – | – |
2021 Q1
2 quarters
|
|
947
Fulgent Genetics
FLGT
$553M
| $930K | ﹤0.01% |
+10,333
| New | +$939K |
2021 Q3
0 quarters
|
|
948
Quanterix
QTRX
$136M
| $930K | ﹤0.01% |
+18,673
| New | +$963K |
2021 Q3
0 quarters
|
|
|
SVFA
949
DELISTED
SVF Investment Corp. Class A Ordinary Shares
SVFA
| $929K | ﹤0.01% |
95,235
| – | – |
2021 Q1
2 quarters
|
|
950
Lamar Advertising Co
LAMR
$15.1B
| $925K | ﹤0.01% |
8,155
+2,921
| +56% | +$320K |
2020 Q4
3 quarters
|
|
Similar funds
NAM
Marshall Wace North America's Q3 2021 Portfolio in Review
As of Q3 2021, Marshall Wace North America held 1,876 positions worth $23.5B, down 2.4% from $24.1B the previous quarter. Its ten largest holdings account for 23% of the portfolio.
Marshall Wace North America's Q3 2021 filing shows 481 new, 362 increased, 407 reduced and 492 closed positions. Its largest new stake was Cisco: 3,779,633 shares worth $206M. The largest sale was Danaher, an estimated $286M.
By sector, the portfolio is most concentrated in Technology at 22% of assets, up from 18% a quarter earlier, followed by Healthcare and Communication Services.
- Marshall Wace North America's largest Q3 2021 buy was Cisco: 3,779,633 shares worth $206M.
- Marshall Wace North America added most to Uber in Q3 2021, an estimated $232M increase.
- Marshall Wace North America's biggest Q3 2021 reduction was Danaher, cutting an estimated $286M.
- Marshall Wace North America fully exited CIMAREX ENERGY CO in Q3 2021, selling an estimated $81.7M.
- Marshall Wace North America's ten largest holdings make up 23% of its $23.5B portfolio in Q3 2021.
- Marshall Wace North America opened 481 new positions and closed 492 in Q3 2021.
- Marshall Wace North America's portfolio value fell 2.4% quarter-over-quarter to $23.5B.
Based on Marshall Wace North America's 13F filing for Q3 2021, filed 15 Nov 2021.